DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more


Nutrilib.com
A comprihensive source of nutritional information

Study Comparing 17B Estradiol/TMG CC 1mg vs. Tibolone in Postmenopausal Women

Information source: Wyeth
Information obtained from ClinicalTrials.gov on November 03, 2008
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Vasomotor Symptoms

Intervention: Intervention 1 Arm 1: 17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined (Drug); Tibolone (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: Wyeth

Official(s) and/or principal investigator(s):
Medical Monitor, Study Director, Affiliation: Wyeth

Overall contact:
Trial Manager, Email: clintrialparticipation@wyeth.com

Summary

This is a Phase IV prospective, randomized, open label, comparative, multicenter study in generally healthy postmenopausal women receiving Totelle (17B Estradiol/TMG CC (1mg)) and Livial (Tibolone).

Clinical Details

Official title: A Prospective, Randomised, Open Label Study to Compare the Efficacy, Safety and Tolerability of 17B Estradiol/TMG CC 1mg and Tibolone in Postmenopausal Women

Study design: Treatment, Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety/Efficacy Study

Primary outcome: Evaluate the efficacy of Totelle and Tibolone in controlling the vasomotor symptoms and cycle control

Secondary outcome: Evaluate the effects of Totelle and Tibolone on tolerability profile defined as: weight changes, breast tenderness; Quality of Life and Adherence to Treatment

Eligibility

Minimum age: 45 Years. Maximum age: 55 Years. Gender(s): Female.

Criteria:

Inclusion Criteria

- Generally healthy postmenopausal women

- Last natural (without exogenous hormone therapy) menstrual cycle completed at least 12

consecutive months prior to screening and without any other kind of gynecological bleeding during this same period

- At least 1 year of natural occurring amenorrhea

Exclusion Criteria

- Known or suspected estrogen-dependent neoplasia

- Endometrial hyperplasia

- Any malignancy with the exception of a history of basal cell carcinoma of the skin

Locations and Contacts

Trial Manager, Email: clintrialparticipation@wyeth.com

Puebla 72410, Mexico; Recruiting

Mexico, DF 6700, Mexico; Recruiting

Mexico, DF 53100, Mexico; Recruiting

Mexico, DF 11000, Mexico; Recruiting

Mexico, DF 11800, Mexico; Not yet recruiting

Monterrey, Nuevo Leon 64060, Mexico; Recruiting

Additional Information

Starting date: February 2006
Ending date: December 2008
Last updated: December 21, 2007

Page last updated: November 03, 2008

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008